Literature DB >> 18586874

The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project.

Traci E Clemons1, Mark C Gillies, Emily Y Chew, Alan C Bird, Tunde Peto, Maria Figueroa, Molly W Harrington.   

Abstract

PURPOSE: To describe vision-targeted health-related quality of life (HR-QOL), measured with the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) in a cohort of patients with macular telangiectasia (MacTel) type 2 and to evaluate the relationship between visual acuity and NEI-VFQ-25 scores.
METHODS: This was an analysis of cross-sectional baseline data from a longitudinal natural history study. Patients with MacTel type 2 were enrolled in the Natural History Study of The Macular Telangiectasia Project (The MacTel Project). NEI-VFQ-25 were completed at enrollment. Linear correlation and regression analyses were used to relate baseline NEI-VFQ-25 overall and subscale scores to visual acuity.
RESULTS: Participants reported lower vision-related functioning measured by the NEI-VFQ-25 in most of the domains measured by the NEI VFQ compared with that of a normal reference group (P < 0.001 for all domains except color vision). Visual acuity was found to be associated with the NEI-VFQ-25 in many of the domains measuring degree of difficulty with common visual activities.
CONCLUSIONS: This is the first cross-sectional cohort study to assess vision targeted HR-QOL in patients with MacTel type 2. Patients with MacTel type 2 reported markedly reduced visual functioning compared to reports of a normal reference group. These findings provide support to the use of the NEI-VFQ-25 in patients with MacTel type 2 to measure the effect of disease and potential therapies on vision-targeted HR-QOL.

Entities:  

Mesh:

Year:  2008        PMID: 18586874      PMCID: PMC3021355          DOI: 10.1167/iovs.08-1749

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  21 in total

1.  Development of the 25-item National Eye Institute Visual Function Questionnaire.

Authors:  C M Mangione; P P Lee; P R Gutierrez; K Spritzer; S Berry; R D Hays
Journal:  Arch Ophthalmol       Date:  2001-07

2.  New design principles for visual acuity letter charts.

Authors:  I L Bailey; J E Lovie
Journal:  Am J Optom Physiol Opt       Date:  1976-11

3.  Visual functioning and general health status in patients with uveitis.

Authors:  R M Schiffman; G Jacobsen; S M Whitcup
Journal:  Arch Ophthalmol       Date:  2001-06

4.  A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasis.

Authors:  J D Gass
Journal:  Arch Ophthalmol       Date:  1968-11

5.  National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10.

Authors:  Traci E Clemons; Emily Y Chew; Susan B Bressler; Wendy McBee
Journal:  Arch Ophthalmol       Date:  2003-02

6.  The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial.

Authors:  S R Cole; R W Beck; P S Moke; R L Gal; D T Long
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-04       Impact factor: 4.799

7.  Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

Authors:  B L Brody; A C Gamst; R A Williams; A R Smith; P W Lau; D Dolnak; M H Rapaport; R M Kaplan; S I Brown
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

8.  Performance and repeatability of the NEI-VFQ-25 in patients with dry eye.

Authors:  Kelly K Nichols; G Lynn Mitchell; Karla Zadnik
Journal:  Cornea       Date:  2002-08       Impact factor: 2.651

9.  Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT).

Authors:  Maureen Maguire
Journal:  Ophthalmology       Date:  2004-07       Impact factor: 12.079

10.  Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia.

Authors:  Peter Charbel Issa; Hans-Martin Helb; Klaus Rohrschneider; Frank G Holz; Hendrik P N Scholl
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

View more
  26 in total

1.  Retinal crystals in type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Irene Leung; Mina Chung; Ute E K Wolf-Schnurrbusch; Alfredo Dubra; David R Williams; Traci Clemons; Daniel Pauleikhoff; Alan C Bird; Tunde Peto
Journal:  Ophthalmology       Date:  2011-08-12       Impact factor: 12.079

2.  Vision-Related Quality of Life in Patients with Ocular Graft-versus-Host Disease.

Authors:  Ujwala S Saboo; Francisco Amparo; Tulio B Abud; Debra A Schaumberg; Reza Dana
Journal:  Ophthalmology       Date:  2015-05-20       Impact factor: 12.079

3.  Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.

Authors:  Gökhan Demir; Özgür Artunay; Mehmet Emin Sucu; Ali Demircan; Dilek Yaşa; Cengiz Alagöz; Mevlüt Celal Öcal
Journal:  Lasers Med Sci       Date:  2018-05-26       Impact factor: 3.161

4.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2010-08-03       Impact factor: 12.079

5.  Comparison of scoring approaches for the NEI VFQ-25 in low vision.

Authors:  Bradley E Dougherty; Mark A Bullimore
Journal:  Optom Vis Sci       Date:  2010-08       Impact factor: 1.973

6.  Adaptive optics microperimetry and OCT images show preserved function and recovery of cone visibility in macular telangiectasia type 2 retinal lesions.

Authors:  Qinyun Wang; William S Tuten; Brandon J Lujan; Jennifer Holland; Paul S Bernstein; Steven D Schwartz; Jacque L Duncan; Austin Roorda
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-13       Impact factor: 4.799

7.  Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

Authors:  Emily Y Chew; Traci E Clemons; Tunde Peto; Ferenc B Sallo; Avner Ingerman; Weng Tao; Lawrence Singerman; Steven D Schwartz; Neal S Peachey; Alan C Bird
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

8.  Prevalence and progression of pigment clumping associated with idiopathic macular telangiectasia type 2.

Authors:  Annal D Meleth; Brian C Toy; Divya Nigam; Elvira Agrón; Robert P Murphy; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2013-04       Impact factor: 4.256

9.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 10.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.